Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure

Abstract Background Treated secondary acute myeloid leukemia (ts-AML)—i.e., AML arising from a previously treated antecedent hematologic disorder—is associated with very poor outcomes. The optimal frontline treatment regimen for these patients is uncertain. Methods We retrospectively analyzed 562 pa...

Full description

Bibliographic Details
Main Authors: Nicholas J. Short, Sangeetha Venugopal, Wei Qiao, Tapan M. Kadia, Farhad Ravandi, Walid Macaron, Courtney D. Dinardo, Naval Daver, Marina Konopleva, Gautam Borthakur, Elizabeth J. Shpall, Uday Popat, Richard E. Champlin, Rohtesh Mehta, Gheath Al-Atrash, Betul Oran, Elias Jabbour, Guillermo Garcia-Manero, Ghayas C. Issa, Guillermo Montalban-Bravo, Musa Yilmaz, Abhishek Maiti, Hagop Kantarjian
Format: Article
Language:English
Published: BMC 2022-01-01
Series:Journal of Hematology & Oncology
Subjects:
Acute myeloid leukemia
Azacitidine
Decitabine
Myelodysplastic syndrome
Chronic myelomonocytic leukemia
Online Access:https://doi.org/10.1186/s13045-022-01229-z

Internet

https://doi.org/10.1186/s13045-022-01229-z

Similar Items